In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs

Experimental Parasitology

Volumn 135, Issue 1, 2013, Pages 36-41

  Maia, Carla ^a,b   Nunes, Mónica ^a   Marques, Mónica ^a   Henriques, Sofia ^a   Rolão, Nuno ^a   Campino, Lenea ^a,c  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b UNIVERSIDADE LUSÓFONA DE HUMANIDADES E TECNOLOGIAS   (Portugal)

^c UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

Chemotherapy; In vitro susceptibility; Leishmania infantum; Portugal; Visceral leishmaniasis

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; MEGLUMINE ANTIMONATE; MILTEFOSINE;

AMASTIGOTE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DISEASE SEVERITY; DOG; DRUG SENSITIVITY; GENETIC HETEROGENEITY; HUMAN; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIASIS; NONHUMAN; PORTUGAL; PRIORITY JOURNAL; PROMASTIGOTE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

CHEMOTHERAPY; IN VITRO SUSCEPTIBILITY; LEISHMANIA INFANTUM; PORTUGAL; VISCERAL LEISHMANIASIS;

ALLOPURINOL; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; DEOXYCHOLIC ACID; DISEASE RESERVOIRS; DOG DISEASES; DOGS; DRUG COMBINATIONS; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; INHIBITORY CONCENTRATION 50; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PARASITIC SENSITIVITY TESTS; PHOSPHORYLCHOLINE;

EID: 84880280839     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2013.05.015     Document Type: Article

References (39)

1. Alvar J., Aparicio P., Aseffa A., Boer M., Cañavate C., Dedet J., Gradoni L., Horst R., López-Vélez R., Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 2008, 21:334-359.
2. Campino L., Maia C. Epidemiology of leishmaniases in Portugal. Acta Méd. Port. 2010, 23:859-864.
3. Campino L., Maia C. The role of reservoirs: canine leishmaniasis. Drug Resistance in Leishmania Parasites - Consequences, Molecular Mechanism and Possible Treatments 2012, 45-64. Springer Verlag, Vienna. A. Ponte-Sucre, M. Padron-Nieves, E. Diaz (Eds.).
4. Campino L., Pratlong F., Abranches P., Rioux J., Santos-Gomes G., Alves-Pires C., Cortes S., Ramada J., Cristovão J.M., Afonso M.O., Dedet J.P. Leishmaniasis in Portugal: enzyme polymorphism of Leishmania infantum based on the identification of 213 strains. Trop. Med. Int. Health 2006, 11:1708-1714.
5. Carrió J., Colmenares M., Riera C., Gállego M., Arboix M., Portús M. Leishmania infantum: stage-specific activity of pentavalent antimony related with the assay conditions. Exp. Parasitol. 2000, 95:209-214.
6. Carrió J., Portús M. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. BMC Pharmacol. 2002, 2:11.
7. Carrió J., Riera C., Gállego M., Ribera E., Portús M. In vitro susceptibility of Leishmania infantum to meglumine antimoniate in isolates from repeated leishmaniasis episodes in HIV-coinfected patients. J. Antimicrob. Chemother. 2001, 47:120-121.
8. Carrió J., Riera C., Gállego M., Portús M. In vitro activity of pentavalent antimony derivatives on promastigotes and intracellular amastigotes of Leishmania infantum strains from humans and dogs in Spain. Acta Tropica 2001, 79:179-183.
9. Choudhury K., Zander D., Kube M., Reinhardt R., Clos J. Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII. Int. J. Parasitol. 2008, 38:1411-1423.
10. Cojean S., Houzé S., Haouchine D., Huteau F., Lariven S., Hubert V., Michard F., Bories C., Pratlong F., Le Bras J., Loiseau P.M., Matheron S. Leishmania resistance to miltefosine associated with genetic marker. Emerg. Infect. Dis. 2012, 18:704-706.
11. Cortes S., Vaz Y., Neves R., Maia C., Cardoso L., Campino L. Risk factors for canine leishmaniasis - a Portuguese national survey. Vet. Parasitol. 2012, 189:189-196.
12. Croft S., Olliaro P. Leishmaniasis chemotherapy - challenges and opportunities. Clin. Microbiol. Infect. 2011, 17:1478-1483.
13. Croft S., Sundar S., Fairlamb A. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19:111-126.
14. Dey T., Afrin F., Anam K., Ali N. Infectivity and virulence of Leishmania donovani promastigotes: a role for media, source, and strain of parasite. J. Eukaryot. Microbiol. 2002, 49:270-274.
15. Duprey Z., Steurer F., Rooney J., Kirchhoff L., Jackson J., Rowton E., Dchantz P. Canine visceral leishmaniasis, United States and Canada, 2000-2003. Emerg. Infect. Dis. 2006, 12:440-446.
16. Durand R., Paul M., Pratlong F., Rivollet D., Dubreuil-Lemaire M., Houin R., Astier A., Deniau M. Leishmania infantum: lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis. Antimicrob. Agents Chemother. 1998, 42:2141-2143.
17. Escobar P., Matu S., Marques C., Croft S. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Tropica 2002, 81:151-157.
18. Faraut-Gambarelli F., Piarroux R., Deniau M., Giusiano B., Marty P., Michel G., Faugère B., Dumon H. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother. 1997, 41:827-830.
19. Farca A., Miniscalco B., Badino P., Odore R., Monticelli P., Trisciuoglio A., Ferroglio E. Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum. Parasitol. Res. 2012, 110:2509-2513.
20. Fumarola L., Spinelli R., Brandonisio O. In vitro assays for evaluation of drug activity against Leishmania spp. Res. Microbiol. 2004, 155:224-230.
21. Gradoni L., Soteriadou K., Seridi N., Louzir H., Dakkak A., Ozensoy S., Jaffe C., Dedet J., Campino L., Cañavate C., Dujardin J. Drug regimens for visceral leishmaniasis in Mediterranean countries. Trop. Med. Int. Health 2008, 13:1-5.
22. Gramiccia M., Gradoni L., Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann. Trop. Med. Parasitol. 1992, 86:613-620.
23. Luz R., Melo M., Dujardin J., Maes L. Post-treatment Sb-susceptibility of Leishmania infantum clinical isolates of dogs. Fourth World Congress on Leishmaniasis 2009, 273.
24. Maia C., Rolão N., Nunes M., Campino L. Infectivity of Leishmania infantum treated with amphotericin B plus Phlebotomus salivary gland in BALB/c mice. Int. J. Integr. Biol. 2009, 6:105-111.
25. Maia C., Rolão N., Nunes M., Gonçalves L., Campino L. Infectivity of five different types of macrophages by Leishmania infantum. Acta Tropica 2007, 90:123-126.
26. Morais-Teixeira E., Damasceno Q., Galuppo M., Romanha A., Rabello A. The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil. Mem. Inst. Oswaldo Cruz 2011, 106:475-478.
27. Natera S., Machuca C., Padrón-Nieves M., Romero A., Díaz E., Ponte-Sucre A. Leishmania spp.: proficiency of drug-resistant parasites. Int. J. Antimicrob. Agents 2007, 29:637-642.
28. Pérez-Victoria F., Sánchez-Cañete M., Seifert K., Croft S., Sundar S., Castanys S., Gamarro F. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist. Updat. 2006, 9:26-39.
29. Piñero J., Martínez S., Castillo A., Portús M., Valladares B. In vitro susceptibility of Leishmania infantum strains isolated from Spanish HIV-positive patients to Abelcet and Fungizone. J. Antimicrob. Chemother. 2002, 50:304-306.
30. Ravel C., Cortes S., Pratlong F., Morio F., Dedet J., Campino L. First report of genetic hybrids between two very divergent Leishmania species: Leishmania infantum and Leishmania major. Int. J. Parasitol. 2006, 36:1383-1388.
31. Saridomichelakis M., Mylonakis M., Leontides L., Billinis C., Koutinas A., Galatos A., Gouletsou P., Diakou A., Kontos V. Periodic administration of allopurinol is not effective for the prevention of canine leishmaniosis (Leishmania infantum) in the endemic areas. Vet. Parasitol. 2005, 130:199-205.
32. Sereno D., Cordeiro da Silva A., Mathieu-Daude F., Ouaissi A. Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol. Int. 2007, 56:3-7.
33. Sereno D., Maia C., Aït-Oudhia K. Antimony resistance and environment: elusive links to explore during Leishmania life cycle. Int. J. Parasitol. Drugs Drug Resist. 2012, 2:200-203.
34. Solano-Gallego L., Koutinas A., Miró G., Cardoso L., Pennisi M., Ferrer L., Bourdeau P., Oliva G., Baneth G. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet. Parasitol. 2009, 165:1-18.
35. Vermeersch M., da Luz R., Toté K., Timmermans J., Cos P., Maes L. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob. Agents Chemother. 2009, 53:3855-3859.
36. Volf P., Benkova I., Myskova J., Sadlova J., Campino L., Ravel C. Increased transmission potential of Leishmania major/Leishmania infantum hybrids. Int. J. Parasitol. 2007, 37:589-593.
37. WHO, 2010. Working to overcome the global impact of neglected tropical diseases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases No. 949, Geneva, Switzerland.
38. WHO, 2005. Report of a WHO informal consultation on liposomal amphotericin B in the treatment of visceral leishmaniasis. WHO/CDS/NTD/IDM/2007.4: Rome, Italy.
39. Williams C., Espinosa O., Montenegro H., Cubilla L., Capson T., Ortega-Barría E., Romero L. Hydrosoluble formazan XTT: its application to natural products drug discovery for Leishmania. J. Microbiol. Methods 2003, 55:813-816.